[1] CARPENTER G, COHEN S. Epidermal growth factor [J]. Journal of Biological Chemistry, 1990, 265(14): 7709-7712.
[2] PAO W, MILLER V A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions [J]. J Clin Oncol, 2005, 23(11): 2556-2568.
[3] RITTER C A, ARTEAGA C L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid
tumors [J]. Semin Oncol, 2003, 30(S1): 3-11.
[4] YATABE Y, KERR K M, UTOMO A, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter
diagnostic survey [J]. J Thorac Oncol, 2015, 10(3): 438-445.
[5] ROSELL R, MORAN T, QUERALT C, et al. Screening for epidermal growth factor receptor mutations in lung cancer [J]. NEngl J Med, 2009, 361(10): 958-967.
[6] ANGELO S P, PIETANZA M C, JOHNSON M L, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from
men and cigarette smokers with lung adenocarcinomas [J]. J Clin Oncol, 2011, 29(15): 2066-2070.
[7] The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma [J]. Nature, 2014,
511(7511): 543-550.
[8] SHI Y, AU J S, THONGPRASERT S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) [J]. J Thorac Oncol, 2014, 9(2): 154-162.
[9] TSAO A S, TANG X M, SABLOFF B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung
cancer [J]. J Thorac Oncol, 2006, 1(3): 231-239.
[10] SKOV B G, HOGDALL E, CLEMENTSEN P, et al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population [J]. APMIS, 2015, 123(2): 108-115.
[11] SHTIEGMAN K, KOCHUPURAKKAL B S, ZWANG Y, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers
prolonged signaling [J]. Oncogene, 2007, 26(49): 6968-6978.
[12] LYNCH T J, BELL D W, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350(21): 2129-2139.
[13] MITSUDOMI T, KOSAKA T, ENDOH H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence [J]. J Clin Oncol, 2005, 23(11): 2513-2520.
[14] ARCILA M E, OXNARD G R, NAFA K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and
enhanced detection of the T790M mutation using a locked nucleic acid-based assay [J]. Clin Cancer Res, 2011, 17(5): 1169-1180.
[15] MÉNARD L, FLOC'H N, MARTIN M J, et al. Reactivation of mutant-EGFR degradation through Clathrin inhibition overcomes
resistance to EGFR tyrosine kinase inhibitors [J]. Cancer Research, 2018, 78(12): 3267-3279.
[16] YAO N, WANG C R, LIU M Q, et al. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive
NSCLC growth [J]. Signal Transduction and Targeted Therapy, 2020, 5(1): 214.
[17] SAKAMOTO K M, KIM K B, KUMAGAI A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box
complex for ubiquitination and degradation [J]. Proc Natl Acad Sci USA, 2001, 98(15): 8554-8559.
[18] HOCHSTRASSER M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation [J]. Current Opinion in Cell
Biology, 1995, 7(2): 215-223.
[19] LIU J, MA J, LIU Y, et al. PROTACs: a novel strategy for cancer therapy [J]. Semin Cancer Biol, 2020, 67: 171-179.
[20] SUN X, GAO H, YANG Y, et al. PROTACs: great opportunities for academia and industry [J]. Sig Transduct Target Ther, 2019, 4: 64.
[21] CHENG M, YU X, LU K, et al. Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-
molecule degraders [J]. J Med Chem, 2020, 63(3): 1216-1232.
[22] HE K, ZHANG Z, WANG W, et al. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an
EGFR degraders based on osimertinib and lenalidomide [J]. Bioorg Med Chem Lett, 2020, 30(12): 127167.
[23] QU X, LIU H, SONG X, et al. Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs
through both proteosome and autophagy/lysosome degradation systems [J]. Eur J Med Chem, 2021, 218(2): 113328.
[24] ZHANG H, ZHAO H Y, XI X X, et al. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC) [J]. Eur J Med Chem, 2020, 189: 112061.
[25] ZHANG X, XU F, TONG L, et al. Design and synthesis of selective degraders of EGFR(L858R/T790M) mutant [J]. Eur J Med Chem, 2020, 192: 112199.
[26] BURSLEM G M, SMITH B E, LAI A C, et al. The advantages of targeted protein degradation over inhibition: An RTK case study [J]. Cell Chem Biol, 2018, 25(1): 67-77. e3.
[27] ZHAO H Y, YANG X Y, LEI H, et al. Discovery of potent small molecule PROTACs targeting mutant EGFR [J]. Eur J Med Chem,
2020, 208: 112781.
[28] BANIK S M, PEDRAM K, WISNOVSKY S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins [J].
Nature, 2020, 584(7820): 291-297.
[29] COUTINHO M F, PRATA M J, ALVES S. A shortcut to the lysosome: the mannose-6-phosphate-independent pathway [J]. Mol
Genet Metab, 2012, 107(3): 257-266.
[30] GHOSH P, DAHMS N M, KORNFELD S. Mannose 6-phosphate receptors: new twists in the tale [J]. Nat Rev Mol Cell Biol, 2003,
4(3): 202-212.
[31] BRAULKE T, BONIFACINO J S. Sorting of lysosomal proteins [J].Biochim Biophys Acta, 2009, 1793(4): 605-614.
[32] KYLE J W, NOLAN C M, OSHIMA A, et al. Expression of human cation-independent mannose 6-phosphate receptor cDNA in
receptor-negative mouse P388D1 cells following gene transfer [J]. Journal of Biological Chemistry, 1988, 263(31): 16230-16235.
[33] LOBEL P, FUJIMOTO K, YE R D, et al. Mutations in the cytoplasmic domain of the 275 kd mannose 6-phosphate receptor
differentially alter lysosomal enzyme sorting and endocytosis [J]. Cell, 1989, 57(5): 787-796.
[34] STEIN M, ZIJDERHAND-BLEEKEMOLEN J E, GEUZE H, et al. Mr 46,000 mannose 6-phosphate specific receptor: its role in
targeting of lysosomal enzymes [J]. EMBO J, 1987, 6(9): 2677-2681.
[35] MOIOLA M, MEMEO M G, QUADRELLI P. Stapled peptides—a useful improvement for peptide-based drugs [J]. Molecules, 2019, 24(20): 3654.
[36] LAU Y H, DE ANDRADE P, QUAH S-T, et al. Functionalised staple linkages for modulating the cellular activity of stapled peptides [J]. Chem Sci, 2014, 5(5): 1804-1809.
[37] WALENSKY L D, BIRD G H. Hydrocarbon-stapled peptides: principles, practice, and progress [J]. J Med Chem, 2014, 57(15):
6275-6288.
[38] YU J J, ZHOU D D, YANG X X, et al. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target [J]. Nat Commun, 2020, 11(1): 3660.
[39] TAKAHASHI D, MORIYAMA J, NAKAMURA T, et al. AUTACs: Cargo-specific degraders using selective autophagy [J]. Mol Cell,
2019, 76(5): 797-810. e10.
[40] LI Z, WANG C, WANG Z, et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds [J]. Nature, 2019, 575(7781): 203-209.
[41] TAKAHASHI D, ARIMOTO H. Targeting selective autophagy by AUTAC degraders [J]. Autophagy, 2020, 16(4): 765-766.
